BridgeBio Pharma (BBIO) reported record annual revenue of $432 million for 2025, fueled by robust commercial performance of its rare disease drug Attruby. The results surpassed analyst expectations and underscored the company’s growing traction in the specialty biopharma market.
- BBIO reported $432 million in 2025 revenue, a record high for the company.
- Attruby contributed $329 million in revenue, up 78% YoY.
- Adjusted EBITDA reached $147 million, up 62% from 2024.
- BBIO exceeded consensus revenue estimates by $37 million.
- The stock rose 12% in after-hours trading following results.
- Sector ETF XLV and peer BMY saw positive movement, reflecting broader biotech momentum.
BridgeBio Pharma (BBIO) delivered a standout financial performance in 2025, achieving $432 million in revenue—the highest in the company’s history—driven primarily by the continued commercial success of its FDA-approved therapy Attruby. The drug, used in the treatment of a rare genetic disorder, saw a 78% year-over-year increase in revenue, contributing $329 million to the total. This performance significantly outpaced the consensus revenue estimate of $395 million, reflecting strong market adoption and effective commercialization strategies. The company’s ability to scale commercial operations for Attruby highlights a key inflection point in its business model, transitioning from early-stage development to sustainable, product-led growth. BBIO reported adjusted EBITDA of $147 million for the year, up 62% from 2024, indicating improving operational efficiency despite ongoing R&D investments. The success of Attruby has also strengthened BBIO’s pipeline visibility, with Phase 3 trials underway for two additional investigational therapies targeting orphan indications. The earnings beat triggered immediate market reaction, with BBIO shares rising 12% in after-hours trading. The stock’s momentum extended to broader healthcare equities, with the Xtrackers Biotech ETF (XLV) gaining 2.3% and Bristol Myers Squibb (BMY) seeing a 1.7% uptick, suggesting sector-wide confidence in biopharma growth narratives. Analysts noted that BBIO’s performance validates the commercial viability of niche therapeutic platforms in the current market environment.